Since receiving FDA approval in 2017, chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in treating patients with certain blood cancers such as lymphoma and leukemia. A complex biomanufacturing process is required to produce the therapy, which is performed for each individual patient. The process begins with apheresis, generating a leukopak containing the patient’s white blood cells. From there, T cells are isolated, genetically engineered to create CAR proteins that enable T cells to attack cancer cells, and multiplied in a laboratory. They are then reintroduced to the patient.
Anschutz Health Sciences Building
1890 N Revere Ct
Aurora, CO 80045